drugset / Trial / NCT05794243
A Multiple-Dose Study of LY3493269 in Healthy Participants
RandomizedParallel-groupOpen-labelBasic science
Summary
The main purpose of this study is to conduct blood tests to measure how much LY3493269 is in the bloodstream and how the body handles and eliminates LY3493269 when administered orally as test compared to reference formulations in healthy participants in fed and/or fasted states. The study will also evaluate the safety and tolerability of LY3493269 in these participants. The study will last up to 43 days excluding the screening period.
Timeline
- Start
- 2023-03-23
- Primary completion
- 2023-06-20
- Completion
- 2023-06-20
Outcome
Outcome not reported
Stopped: “Following preplanned review of the safety and pharmacokinetic data from Part A, it was determined that sufficient data had been obtained. The decision was made to not proceed with Part B and the study was terminated early.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3493269 | Unknown | 4 mg | Oral |
| Background | Salcaprozate Sodium | Unknown | 300 mg | Oral |
| Background | Sodium Caprate | Unknown | 280 mg | Oral |
Indications
No indication recorded.